2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
04:00 p.m. - 05:30 p.m.
MCCNO - New Orleans Theatre A
Technology and Procedures, Assays, Imaging, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Gene Editing, Profiling, Treatment Considerations, Biological Therapies, (CAR)-T Cell Therapies, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphomas, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Study Population, Human, Adult, Animal Model
PAPER

402 Perivascular sequestration of T cells in the pre-treatment microenvironment is associated with CAR T-cell failure in large B-cell lymphoma

Yuanning Zheng, PhD, Arvin Eslami, MD2, Dasom (Caroline) Lee, MD3, Sheren Younes, MD, PhD4, Haiyu Zhang5, Shuchun Zhao6, Jingyu Xu7, Jane Z. Feng8, Mathew J. Frank, MD, PhD9, Saurabh Dahiya, MD, FACP10, Ash A. Alizadeh, MD, PhD11, Olivier Gevaert, PhD12, Yasodha Natkunam, MD, PhD13, David Miklos, MD, PhD14, Zinaida Good, PhD15
1 Stanford University, Stanford, California, United States, Stanford University, Stanford, California, United States, Stanford University, Stanford, California, United States, Stanford University, Stanford, California, United States
2 Stanford University, Stanford, California, United States, Stanford University, Stanford, California, United States, Stanford University, Stanford, California, United States, Stanford University, Stanford, California, United States
3 Stanford University, Stanford, California, United States, Stanford University, Stanford, California, United States
4 Stanford University, Stanford, California, United States
5 Stanford University, Stanford, California, United States
6 Stanford University, Stanford, California, United States
7 Stanford University, Stanford, California, United States, Stanford University, Stanford, California, United States, Stanford University, Stanford, California, United States
8 Stanford University, Stanford, California, United States, Stanford University, Stanford, California, United States, Stanford University, Stanford, California, United States
9 Stanford University, Stanford, California, United States, Stanford University, Stanford, California, United States
10 Stanford University, Stanford, California, United States, Stanford University, Stanford, California, United States
11 Stanford University, Stanford, California, United States
12 Stanford University, Stanford, California, United States, Stanford University, Stanford, California, United States, University of California, San Francisco and Stanford University, San Francisco, California, United States
13 Stanford University, Stanford, California, United States
14 Stanford University, Stanford, California, United States, Stanford University, Stanford, California, United States, University of California, San Francisco and Stanford University, San Francisco, California, United States
15 Stanford University, Stanford, California, United States, Stanford University, Stanford, California, United States, Stanford University, Stanford, California, United States, Stanford University, Stanford, California, United States, University of California, San Francisco and Stanford University, San Francisco, California, United States

Background: Chimeric antigen receptor (CAR) T cell therapy has transformed outcomes in relapsed/refractory (r/r) large B-cell lymphoma (LBCL), but approximately half of patients relapse or progress after therapy, and pretreatment biomarkers of CAR T-cell failure remain limited. The tumor microenvironment (TME), defined by the spatial organization of tumor, immune, and stromal cells and their local signaling interactions, is increasingly implicated in shaping T-cell fitness and therapeutic response. Emerging evidence has revealed that vascular and stromal architecture may regulate T-cell trafficking, positioning, and access to tumor cells in LBCL (Lenz et al. NEJM, 2008; Tobiasova et al. J Transl Res, 2026). However, the spatial architecture in CAR T-treated LBCL has not been systematically mapped at single-cell resolution. We therefore hypothesized that the vascular-stromal architecture of the pretreatment lymphoma microenvironment influences T-cell access to tumor cells and is associated with subsequent response to axicabtagene ciloleucel (axi-cel).

Methods: We generated single-cell spatial transcriptomic profiles of 1.34 million cells from 11 tissue microarrays representing 124 patients who received axi-cel (two 0.6-mm cores per case), using the CosMx Spatial Molecular Imager with the Human 6K Discovery Panel. After exclusion of incomplete or highly necrotic cores and samples collected after CAR T-cell therapy, evaluable pretreatment LBCL tissues from 70 patients were retained for downstream analyses. The median follow-up duration was 30.6 months (IQR, 12.4-39.2 months). We developed computational frameworks for cell type annotation, neighborhood discovery, and spatial interaction modeling. Patient-level comparisons were performed using linear mixed-effects models (LMEM), and tissue-level differences were evaluated using the Wilcoxon Rank-Sum test.

Results: Pretreatment tissues from patients who failed to achieve a durable response at 6 months showed enrichment of vascular stromal populations. Vascular smooth muscle cells were significantly more abundant in progressors than responders (n = 28 vs. 42; LMEM T = 2.33, P = 0.02), and blood vascular and lymphatic endothelial cells showed similar trends. Patients with vascular cell proportions above the cohort median of 2.74% had shorter progression-free survival (PFS) than those below the median (log-rank P = 0.02).

Spatial analyses supported a model of vascular-associated immune exclusion. CD4 and CD8 T cells were positioned closer to vascular cells in tissues from progressors at 6 months than responders (mean distance 76.2 μm vs. 95.2 μm; LMEM T = −2.62, P < 0.02). In parallel, permutation-based cell-cell interaction analysis showed that the likelihood of spatial interactions between T cells and B cells were significantly reduced in progressors (LMEM T = −2.18, P = 0.03), whereas fibroblast and vascular cell interactions were increased (LMEM T = 2.41, P = 0.02), consistent with increased local aggregation of stromal cells.

We next examined whether vascular proximity was associated with distinct endogenous T-cell states. T cells located within 50 μm of vascular cells exhibited higher naïve (rank-biserial correlation = 0.43; Wilcoxon P = 0.005) and adhesion-associated (rank-biserial correlation = 0.40; Wilcoxon P = 0.006) expression programs than those located farther away. Conversely, T cells located more than 50 μm from vascular cells showed higher cytotoxic (rank-biserial correlation = 0.31; Wilcoxon P = 0.04) and glycolytic programs (rank-biserial correlation = 0.31; Wilcoxon P = 0.04).

Conclusion: Together, these results identify a vascular stroma-rich spatial architecture associated with inferior CAR T outcomes in r/r LBCL. Increased vascular stromal content, perivascular T-cell localization, and reduced T-cell and tumor cell spatial interactions support a model in which vascular-associated stromal niches may limit productive T-cell engagement with malignant B cells and favor less cytotoxic endogenous T-cell states. Pretreatment vascular stromal content may serve as a spatial biomarker of axi-cel resistance and nominate stromal remodeling or trafficking barriers as candidate mechanisms to enhance T-cell tumor infiltration. Since these analyses reflect endogenous T cells in pretreatment tissue, validation in independent cohorts, across other CAR T-cell products, and in post-infusion samples is ongoing.

Jane Z. Feng: No relevant conflicts of interest to declare.